| Secondary |
| Rheumatoid Arthritis |
40.2% |
| Prophylaxis |
6.4% |
| Immunosuppression |
6.1% |
| Langerhans' Cell Histiocytosis |
5.7% |
| Prophylaxis Against Transplant Rejection |
5.7% |
| Product Used For Unknown Indication |
5.0% |
| Stem Cell Transplant |
4.3% |
| Allogenic Bone Marrow Transplantation Therapy |
4.0% |
| Diabetes Mellitus |
2.6% |
| Hypertension |
2.6% |
| Immunosuppressant Drug Therapy |
2.6% |
| Nephrotic Syndrome |
2.4% |
| Osteoporosis |
2.1% |
| Renal Transplant |
2.1% |
| Diffuse Large B-cell Lymphoma |
1.4% |
| Graft Versus Host Disease In Skin |
1.4% |
| Ophthalmic Herpes Simplex |
1.4% |
| Prophylaxis Against Graft Versus Host Disease |
1.4% |
| Transplant |
1.4% |
| Cord Blood Transplant Therapy |
1.2% |
|
| Pyrexia |
10.5% |
| Weight Decreased |
10.5% |
| Bone Tuberculosis |
8.8% |
| Sepsis |
7.0% |
| Organising Pneumonia |
5.3% |
| Pneumonia |
5.3% |
| Respiratory Disorder |
5.3% |
| Thrombotic Microangiopathy |
5.3% |
| Upper Respiratory Tract Inflammation |
5.3% |
| Wheezing |
5.3% |
| Acute Psychosis |
3.5% |
| Device Related Infection |
3.5% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
3.5% |
| Pleural Infection Bacterial |
3.5% |
| Rheumatoid Lung |
3.5% |
| Venoocclusive Liver Disease |
3.5% |
| Viral Test Positive |
3.5% |
| White Blood Cell Count Decreased |
3.5% |
| Acute Graft Versus Host Disease |
1.8% |
| Bone Hyperpigmentation |
1.8% |
|
| Concomitant |
| Rheumatoid Arthritis |
28.5% |
| Immunosuppression |
9.2% |
| Prophylaxis Against Transplant Rejection |
8.8% |
| Prophylaxis |
8.4% |
| Prophylaxis Against Graft Versus Host Disease |
7.0% |
| Allogenic Bone Marrow Transplantation Therapy |
6.6% |
| Drug Use For Unknown Indication |
5.9% |
| Adverse Event |
4.4% |
| Stem Cell Transplant |
3.6% |
| Cord Blood Transplant Therapy |
3.4% |
| Hypertension |
3.2% |
| Acute Lymphocytic Leukaemia |
1.5% |
| Product Used For Unknown Indication |
1.5% |
| Bone Marrow Transplant |
1.4% |
| Immunosuppressant Drug Therapy |
1.2% |
| Infection Prophylaxis |
1.1% |
| Acute Myeloid Leukaemia |
1.1% |
| Graft Versus Host Disease |
1.1% |
| Renal Transplant |
1.0% |
| Angina Pectoris |
0.9% |
|
| Febrile Neutropenia |
10.2% |
| Thrombotic Microangiopathy |
8.6% |
| Cerebral Infarction |
7.0% |
| Pneumonia |
7.0% |
| Glucose Tolerance Impaired |
6.3% |
| Histiocytosis Haematophagic |
5.5% |
| White Blood Cell Count Decreased |
5.5% |
| Pleural Effusion |
4.7% |
| Shock |
4.7% |
| Sputum Increased |
4.7% |
| Urticaria |
4.7% |
| Venoocclusive Liver Disease |
4.7% |
| Focal Segmental Glomerulosclerosis |
3.9% |
| Renal Impairment |
3.9% |
| Staphylococcal Sepsis |
3.9% |
| Mucous Membrane Disorder |
3.1% |
| Sepsis |
3.1% |
| Septic Shock |
3.1% |
| Spinal Compression Fracture |
3.1% |
| Deep Vein Thrombosis |
2.3% |
|
| Interacting |
| Immunosuppressant Drug Therapy |
41.9% |
| Product Used For Unknown Indication |
19.4% |
| Liver Transplant |
9.7% |
| Infection Prophylaxis |
6.5% |
| Oral Candidiasis |
6.5% |
| Tachycardia |
6.5% |
| Infection |
3.2% |
| Oesophageal Candidiasis |
3.2% |
| Steroid Therapy |
3.2% |
|
| Drug Interaction |
40.0% |
| Renal Failure Acute |
40.0% |
| Drug Level Increased |
20.0% |
|
